Bacillus Calmette-Guerin (BCG) and antigen presenting cells for treatment of bladder cancer
Combination therapeutics for the treatment of cancer include the use of immune effector cells, IL-15 based superagonists and one or more immunotherapeutic agents such as Bacillus Calmette-Guerin (BCG).
1. A vaccine composition comprising:
1) immunotherapeutic primed antigen presenting cells, wherein the antigen presenting cells are isolated from a urine sample or bladder mucosa of an immunotherapeutic treated subject; and
2) an IL-15:IL-15Rα fusion protein complex, wherein the antigen presenting cells are exposed ex-vivo to the IL-15:IL-15Rα fusion protein complex.
2. The vaccine composition of claim 1 wherein the IL-15:IL-15Rα complex comprises an IL-15N72D:IL-15RαSu/Fc complex.
3. The vaccine composition of claim 2 , wherein the IL-15N72D:IL-15RαSu/Fc complex comprises a dimeric IL-15RαSu/Fc and two IL-15N72D molecules.
4. The vaccine composition of claim 3 , wherein the IL-15N72D:IL-15RαSu/Fc complex is N-803.
5. The vaccine composition of claim 1 , wherein the antigen presenting cells are isolated from a subject diagnosed with a neoplastic disease or cancer.
6. The vaccine composition of claim 1 , wherein the antigen presenting cells are isolated from a subject diagnosed with urothelial/bladder carcinoma.
7. The vaccine composition of claim 1 , wherein the antigen presenting cells comprise dendritic cells, mast cells, myeloid derived phagocytes or combinations thereof.
8. The vaccine composition of claim 1 , wherein the antigen presenting cells are loaded ex vivo with tumor antigens.
9. The vaccine composition of claim 1 , wherein the vaccine composition is formulated in an administration mode selected from the group consisting of systemic, intravenous, local, subcutaneous, intramuscular, inhalation and intraperitoneal.
10. The vaccine composition of claim 1 , wherein the immunotherapeutic comprises Bacillus Calmette-Guerin (BCG) and/or an IL-15N72D:IL-15RαSu/Fc complex.
11. The vaccine composition of claim 1 , wherein the immunotherapeutic comprises BCG.
12. The vaccine composition of claim 1 , wherein the vaccine composition is for use in the treatment of neoplastic disease or cancer.
13. The vaccine composition of claim 12 , wherein the neoplastic disease or cancer comprises bladder cancer, a glioblastoma, prostate cancer, hematological cancer, B-cell neoplasms, multiple myeloma, B-cell lymphoma, Hodgkin's lymphoma, chronic lymphocytic leukemia, acute myeloid leukemia, cutaneous T-cell lymphoma, T-cell lymphoma, a solid tumor, urothelial/bladder carcinoma, melanoma, lung cancer, renal cell carcinoma, breast cancer, gastric and esophageal cancer, head and neck cancer, colorectal cancer, ovarian cancer, non-small cell lung carcinoma, B cell non-Hodgkin lymphoma, squamous cell head or neck carcinoma, or urothelial/bladder carcinoma.
14. The vaccine composition of claim 12 , wherein the neoplastic disease or cancer comprises urothelial/bladder carcinoma.
15. The vaccine composition of claim 12 , wherein the treatment further comprises radiation, chemotherapy, surgery, a therapeutic antibody, an immunomodulatory agent, a proteasome inhibitor, a pan-DAC inhibitor, an H-DAC inhibitor, a checkpoint inhibitor, an adoptive cell therapy comprising a CAR T and/or an NK cell therapy, and/or a vaccine.
16. A kit for use in the treatment of bladder cancer, the kit comprising:
1) an immunotherapeutic agent for use in the treatment of a patient having bladder cancer;
2) an effective amount of antigen presenting cells, wherein the antigen presenting cells have been isolated from bladder mucosa of the treated patient;
3) an IL-15:IL-15Rα fusion protein complex; and
4) directions for the treatment of the cancer.
17. The kit of claim 16 , wherein the immunotherapeutic agent comprises Bacillus Calmette-Guerin (BCG) and/or wherein the IL-15:IL15Rα fusion protein complex comprises an IL-15N72D:IL-15RαSu/Fc complex (N-803).